Bioconjugate chemistry

Lipid Nanoparticles Carrying αHTRA1 mRNA May Improve Pancreatic Cancer’s Oxidative Balance by Reducing HTRA1 and HIF-1 Signals

Updated

Abstract

The developed mRNA drug targeting HTRA1 shows potential to inhibit the malignant phenotype of pancreatic ductal adenocarcinoma (PDAC) cells.

  • High-temperature requirement protein A1 (HTRA1) is found to be upregulated in PDAC and contributes to disease progression.
  • Lipid nanoparticles (LNP) enhance the delivery and effectiveness of mRNA drugs targeting HTRA1 in tumor cells.
  • The anti-HTRA1 mRNA effectively inhibits the malignant characteristics of PDAC cells in vitro.
  • In mouse models, the mRNA drug may improve the tumor microenvironment by inhibiting the HIF-1 signaling pathway.
  • The findings suggest that mRNA drugs based on LNP could provide new options for targeted therapy in PDAC.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free